homepage-top-section

Under the agreement, Apotex will acquire Cumberland’s branded medicines for cash, subject to approval by Cumberland’s shareholders. The partnership aims to establish a robust platform for speciality medicines

The collaboration aims to implement an agentic platform across MSD’s research and development (R&D), commercial, manufacturing and corporate divisions, with Google Cloud engineers working directly with MSD teams

The approval covers Bosaya in a 60mg/ml prefilled syringe and Vevzuo in a 120mg/1.7ml (70mg/ml) single-dose vial, both for subcutaneous injection. Denosumab therapies are used to increase bone

The move comes after Asahi Kasei signed a definitive agreement to acquire all issued shares of Aicuris for approximately €780m ($920.7m) earlier this year. The acquisition aligns with Asahi Kasei’s

This approval authorises Enflonsia’s marketing across all 27 European Union member states, Iceland, Liechtenstein and Norway. Enflonsia is a long-acting monoclonal antibody intended for prevention, providing protection over

The agreement involves Daiichi Sankyo Research Institute Boston and aims to assess the use of Interna’s MNM technology as a delivery enhancer for therapeutic modalities. Interna’s MNM molecules

This Phase Ib/II study will measure the tolerability, safety, and early clinical activity by combining Boehringer Ingelheim’s DLL3 / cluster of differentiation 3 (CD3) T-cell engager, obrixtamig, with

The acquisition includes the lead candidate CBB-120, a dual-payload antibody-drug conjugate (ADC) developed to treat cancer. The therapy is anticipated to have a US Food and Drug Administration

The treatment targets adult patients with ES-SCLC who have experienced disease progression on or after platinum-based chemotherapy. The FDA has scheduled a decision date for 10 October 2026